0001683168-23-002095.txt : 20230331
0001683168-23-002095.hdr.sgml : 20230331
20230331192810
ACCESSION NUMBER: 0001683168-23-002095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230329
FILED AS OF DATE: 20230331
DATE AS OF CHANGE: 20230331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Downs Christopher
CENTRAL INDEX KEY: 0001705978
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39126
FILM NUMBER: 23789903
MAIL ADDRESS:
STREET 1: 31700 RESEARCH PARK DRIVE
CITY: MADISON HEIGHTS
STATE: MI
ZIP: 48071
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001729427
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822318545
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
BUSINESS PHONE: 1-800-946-9185
MAIL ADDRESS:
STREET 1: 2100 WEST LOOP SOUTH
STREET 2: SUITE 900
CITY: HOUSTON
STATE: TX
ZIP: 77027
4
1
ownership.xml
X0407
4
2023-03-29
0
0001729427
CNS Pharmaceuticals, Inc.
CNSP
0001705978
Downs Christopher
C/O CNS PHARMACEUTICALS, INC.
2100 WEST LOOP SOUTH, SUITE 900
HOUSTON
TX
77027
0
1
0
0
Chief Financial Officer
0
Restricted Stock Units
2023-03-29
4
A
0
6067
A
Common stock
6067
28768
D
Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).
Issued in connection with the reporting person's employment with the Company.
/s/ Christopher Downs
2023-03-31